Cor Vasa 2011, 53(6-7):343-347 | DOI: 10.33678/cor.2011.085

Use of spironolactone in the treatment of resistant arterial hypertension

Jan Václavík*, Eva Kociánová, Miloš Táborský
Centrum pro diagnostiku a léčbu hypertenze, I. interní klinika - kardiologická, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého, Olomouc, Česká republika

Spironolactone is a mineralocorticoid receptor antagonist which lowers blood pressure. This review article summarizes the results of published trials of spironolactone in patients with resistant arterial hypertension. A number of small, uncontrolled trials showed a pronounced antihypertensive effect of small doses of spironolactone. In the randomized trials, including the recently published ASPIRANT trial, the magnitude of blood pressure fall in the spironolactone group compared to the placebo group was smaller and only systolic blood pressure was lowered significantly. We also discuss the laboratory predictors of blood pressure response to spironolactone treatment.

Keywords: Mineralocorticoid receptor antagonists; Spironolactone; Hypertension; Resistant hypertension; Prediction of response to treatment

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J, Kociánová E, Táborský M. Use of spironolactone in the treatment of resistant arterial hypertension. Cor Vasa. 2011;53(6-7):343-347. doi: 10.33678/cor.2011.085.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-1419. Go to original source... Go to PubMed...
    2. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404. Go to original source... Go to PubMed...
    3. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082. Go to original source... Go to PubMed...
    4. Widimský J Jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008;54:101-118. Go to PubMed...
    5. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585. Go to original source... Go to PubMed...
    6. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68. Go to original source... Go to PubMed...
    7. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006. Go to original source...
    8. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60: 820-825. Go to original source... Go to PubMed...
    9. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev 2010 Aug 4;(8):CD008169. Go to original source... Go to PubMed...
    10. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-3281. Go to original source... Go to PubMed...
    11. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999;131:105-108. Go to original source... Go to PubMed...
    12. Štrauch B, Petrák O, Zelinka T, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008;21:1086-1092. Go to original source... Go to PubMed...
    13. Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-339. Go to original source... Go to PubMed...
    14. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930. Go to original source... Go to PubMed...
    15. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-487. Go to original source... Go to PubMed...
    16. Sharabi Y, Adler E, Shamis A, et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006;19:750-755. Go to original source... Go to PubMed...
    17. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-894. Go to original source... Go to PubMed...
    18. Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845. Go to original source... Go to PubMed...
    19. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30:418-424. Go to original source... Go to PubMed...
    20. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, et al. Aldosterone excess or escape: Treating resistant hypertension. J Clin Hypertens (Greenwich) 2009;11:245-252. Go to original source... Go to PubMed...
    21. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010;28:2329-2335. Go to original source... Go to PubMed...
    22. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147-152. Go to original source... Go to PubMed...
    23. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010;4:290-294. Go to original source... Go to PubMed...
    24. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011;22:75-78. Go to PubMed...
    25. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007;25:747-750. Go to original source... Go to PubMed...
    26. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) - study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155: v tisku. E-pub ahead of print, DOI 10.5507/bp.155.2011.004 Go to original source...
    27. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-1075. Go to original source... Go to PubMed...
    28. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18:50-55. Go to original source... Go to PubMed...
    29. London GM. Role of arterial wall properties in the pathogenesis of systolic hypertension. Am J Hypertens 2005;18:19S-22S. Go to original source... Go to PubMed...
    30. Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens 2010;28:170-177. Go to original source... Go to PubMed...
    31. Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich) 2011;13:120-130. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes